Inclusion Criteria

Inclusion Criteria for Subjects:

- Must have signed Subject Informed Consent form

- Documentation of Disease: All patients must have histologically or cytologically
confirmed non-hematological malignancy that is metastatic or unresectable and for
which standard curative or palliative measures do not exist or are no longer
effective.

- Measurable Disease: Lesions that can be accurately measured in at least one dimension
(longest diameter recorded) as ³20 mm with conventional technique or as ³10 mm with
spiral CT scan.

- Life expectancy of at least 4 months as judged by the PI at the time of consent

- Performance status of ≤2 on the ECOG scale (see Appendix I).

- ≥ 4 weeks since prior medical therapy, radiation therapy, and surgery

- Adequate organ function, such as absolute neutrophils ≥1,500/µl, platelet transfusion
independent,

- platelet count ≥100,000/µl, serum bilirubin ≤2 mg/dl, AST/ALT less than 3x upper
limit of normal and serum creatinine ≤2 mg/dl.

- No uncontrolled diabetes mellitus, significant cardiac disease, e.g. recent
myocardial infarction ≥ within 30 days, or active serious infection.

- No HIV infection and no recent use (within 30 days) of immunosuppressive agents other
than steroids.

- Women should not be pregnant or nursing while participating in this trial. Both men
and women of reproductive potential should agree to use an effective means of birth
control. Women of childbearing potential should have a negative serum pregnancy test
before treatment.

- Negative for HLA Class I & II antibodies.

- Negative neutrophil antibody test.

- No prior history of stem cell transplantation.

- No evidence of brain tumors or metastases.

- No prior history of fludarabine therapy.

Inclusion Criteria for Granulocyte Donors:

- Must have signed Donor-participant Informed Consent Form

- Must be a healthy, eligible blood donor who has completed Full-Length Universal Donor
History Questionnaire version 1.2

- Must be able to donate granulocytes and be willing to undergo granulocyte apheresis

- Must have an HLA profile (A, B, DR) with results that ensure donated granulocytes
will be mismatched with the recipient

- Must have CMV negative or positive sero-testing completed; only seronegative donors
are accepted for a seronegative recipient

- Must have compatible ABO and RH typing with the subject

- Must be negative for HLA Class I & II antibodies

- Must have a negative Neutrophil antibody test

- Must have a negative infectious disease workup within 30 days of apheresis /
donation.

- Must not have any known cardiac illness that could cause a potential risk associated
with leukapheresis.

- Must not have a genetic relationship to the recipient